Abstract
We assessed effectiveness of the BNT162b2 vaccine against infection with the B.1.1.529 (Omicron) variant (mostly BA.1 subvariant), among children 5-11 years of age in Israel. Using a matched case-control design, we matched SARS-CoV-2-positive children (cases) and SARS-CoV-2-negative children (controls) by age, sex, population group, socioeconomic status, and epidemiologic week. Vaccine effectiveness estimates after the second vaccine dose were 58.1% for days 8-14, 53.9% for days 15-21, 46.7% for days 22-28, 44.8% for days 29-35, and 39.5% for days 36-42. Sensitivity analyses by age group and period demonstrated similar results. Vaccine effectiveness against Omicron infection among children 5-11 years of age was lower than vaccine efficacy and vaccine effectiveness against non-Omicron variants, and effectiveness declined early and rapidly.
Original language | English |
---|---|
Pages (from-to) | 771-777 |
Number of pages | 7 |
Journal | Emerging Infectious Diseases |
Volume | 29 |
Issue number | 4 |
DOIs | |
State | Published - Apr 2023 |
Bibliographical note
Publisher Copyright:© 2023 Centers for Disease Control and Prevention (CDC). All rights reserved.
ASJC Scopus subject areas
- Epidemiology
- Microbiology (medical)
- Infectious Diseases